This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox GGC7
From Proteopedia
(Difference between revisions)
| Line 15: | Line 15: | ||
== Disease == | == Disease == | ||
| - | + | A mutation of Glu 111 in the active site will render the enzyme inactive or a mutation at Pro 286 will slow down the enzymatic activity. A low functioning or inactive insulin degrading enzyme will allow the buildup of both insulin and amyloid beta-proteins. | |
| - | + | ||
| - | + | For insulin, if it is allowed to build up, insulin resistance can occur and contribute to the development of type II diabetes. A mutation at Asp 34 will cause Hyperproinsulinemia <ref>doi.org/10.1210/en.135.2.610</ref>, a disease where the body secretes insulin before it has been fully processed (proinsulin) and so does not function properly. | |
| - | + | Several different mutations at birth or a young age can contribute to the onset of neonatal diabetes or type I diabetes. The locations are: Asp 24, Arg 32, Ser 32, Gly 43, Val 47, Cys 48, Cys 89, Cys 90, Tyr 96 and Cys 108. | |
| - | + | ||
| - | + | The buildup of amyloid beta-proteins in the brain has been determined to cause the onset of Alzheimer’s disease <ref>DOI 10.1074/jbc.M900068200</ref>. The onset of Alzheimer’s can also be contributed to the mutation of Ile 714. | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | == Relevance == | ||
| - | == Structural highlights == | ||
| - | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | ||
</StructureSection> | </StructureSection> | ||
Revision as of 03:22, 16 November 2020
Insulin Protease (Insulin Degrading Enzyme)
| |||||||||||
References
- ↑ Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005 May;26(2):19-39. PMID:16278749
- ↑ Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221 doi:10.1038/nature05143
- ↑ Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
- ↑ Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
- ↑ doi.org/10.1210/en.135.2.610
- ↑ Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
